SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (368)1/8/2005 7:36:13 PM
From: Natashya_Fatale  Read Replies (2) | Respond to of 946
 
I think xyotax is a slam dunk replacement for paclitaxel. It's likely going to be approved as a replacement for Taxol in 1st line multimode therapy, ie., one of the platins (carbo or cisplatin) + xyotax.

The Phase I dose escalation in lung cancer in San Antonio has everybody in oncology glued to their seats. At the present rate, it looks like much larger doses of paclitaxel/taxol can be run in on the 1st cycle than ever before, with much less toxicity.

The Phase I in San Antonio at IDD is supposedly yielding excellent results as a monotherapy. Time will tell. Last I heard, they were dosing patients at 135mg/m2 on a weekly cycle.

One of my mentors is shepherding a few Phase 1s at IDD and he echoes their praise of xyotax.

OK, do I get a free xyotax sweatshirt now?

Nicki



To: Biomaven who wrote (368)1/12/2005 10:01:55 PM
From: Robohogs  Read Replies (1) | Respond to of 946
 
The stock here is not that eggregious - $3 MM versus his annual cash comp of about $1 MM (base plus target bonus). I think there should be less base and more risk-based comp. I think I am becoming more liberal in this area and think that CEOs and bankers and fund managers are all way overpaid.

Jon

Good catch, Peter on the optionality of the shares. I like the approach.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News